Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia

The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.

Congenital Adrenal Hyperplasia

Estimated

~$10 – $8,750

Neurocrine Switzerland GmbHNCT07536269

Natural History Study of Patients With Excess Androgen

This study will evaluate and gather information in patients with genetic causes of too much androgen (male-like hormone) in order to better understand the effe…

Congenital Adrenal Hyperplasia (CAH)Familial Male-Limited Precocious Puberty (FMPP)

Estimated

~$10 – $675

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT00250159

Phase 2

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participan…

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

Estimated

~$10 – $8,750

Crinetics Pharmaceuticals Inc.NCT07159841

Phase 3

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

Estimated

~$10 – $8,750

Crinetics Pharmaceuticals Inc.NCT07144163

Evaluation of a Healthcare Transition Protocol for Patients With Congenital Adrenal Hyperplasia

The purpose of this study is to implement and evaluate the feasibility and acceptability of a structured healthcare transition program for adolescents and youn…

Congenital Adrenal Hyperplasia

Estimated

~$10 – $750

University of Alabama at BirminghamNCT07611786

Phase 2

An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (CALM2-CAH)

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

Estimated

~$10 – $8,750

Crinetics Pharmaceuticals Inc.NCT06712823

Phase 1

A Multi-site, Open-label, Sequential-group, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare…

Congenital Adrenal Hyperplasia

Estimated

~$10 – $7,500

H. Lundbeck A/SNCT05669950